Fungi have emerged in the last two decades as major causes of human disease contributing significantly to morbidity and mortality. More specifically, fungal pathogens such as Candida spp, Cryptococcus spp and Aspergillus spp are the leading cause of various forms of mycoses in the US with overall mortality of about 50%. Currently available antifungal therapeutics are limited and have several drawbacks including toxicity to humans, ineffectiveness, and poor oral bioavailability. Therefore, there is a great need to discover and develop new antifungal agents to address these challenges.
Researchers at Kansas State University have identified two synthetic compounds that show strong activity against various species of C. albicans including C. krusei, C. glabarata and azole resistant clinical isolates of C. albicans, Aspergillus nidulans, Cryptococcus spp and dermatophytes. The compounds identified act as broad-spectrum fungicidal compounds against several types of fungal pathogens at low concentrations. When compared to solvent controls, fungi exposed to the identified compounds showed superior inhibition of growth or spore germination. The combination of broad-spectrum antifungal activity, lack of antifungal resistance development of compounds, and their ease of synthesis make them ideal prototypes for future drug development.
-Eliminates current limitations and drawbacks of available fungicides
-Compounds act against various yeasts and fungi that are pathogenic to both humans and animals, possibly plants
-Molecular weights of the two compounds are low enough for drug development and ideal candidates for further modifications and improvements
-Less expensive than current highly complex drugs
-Development of new antifungal agents to treat human and animal fungal diseases
-Control plant pathogenic fungi, mildews and mold that affect agriculture
-Food storage fungi, cattle food spoiling fungi and fruit rot fungi
-U.S. patent #8,980,951 issued on March 17, 2015.